Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus

Abstract

Objectives

The aim of this study was to investigate the association between antiphospholipid antibodies and non-thrombotic and non-gestational manifestations of systemic lupus erythematosus.

Methods

Systemic lupus erythematosus patients with persistently positive antiphospholipid antibodies or lupus anticoagulant were identified and grouped as systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS), systemic lupus erythematosus with positive antiphospholipid antibodies/lupus anticoagulant without antiphospholipid syndrome (SLE-aPL), and systemic lupus erythematosus with negative aPLs (SLE-No aPL). Groups were compared in terms of non-thrombotic systemic lupus erythematosus manifestations and laboratory features retrospectively.

Results

A total of 150 systemic lupus erythematosus patients, 26 with SLE-APS, 25 with SLE-aPL, and 99 with SLE-No aPL, were identified. Livedo reticularis, neurologic involvement, and thrombocytopenia were more common in antiphospholipid antibody positive systemic lupus erythematosus cases. Malar rash, arthritis, and pleuritis were more common in the SLE-No aPL, SLE-APS, and SLE-aPL groups, respectively. Positivity rates and titers of specific antiphospholipid antibodies did not differ between the SLE-APS and SLE-aPL groups.

Conclusions

Presence of antiphospholipid syndrome or persistent antiphospholipid antibodies may be related to non-thrombotic and non-gestational systemic lupus erythematosus manifestations. Patients with systemic lupus erythematosus plus antiphospholipid syndrome and persistent antiphospholipid antibodies without antiphospholipid syndrome also differ in terms of systemic lupus erythematosus manifestations.

Keywords

Antiphospholipid antibody antiphospholipid syndrome lupus anticoagulant systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Harris

Gharavi

Boey

et al.

Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211–1214.

Mackworth-Young

Loizou

Walport

. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48: 362–367.

Shoenfeld

Meroni

Toubi

. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? Curr Opin Rheumatol 2009; 21: 495–500.

Cervera

Piette

Font

et al.

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

Reynaud

Lega

Mismetti

et al.

Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13: 595–608.

Taraborelli

Leuenberger

Lazzaroni

et al.

The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus 2016; 25: 1365–1368.

Zuily

Regnault

Selton-Suty

et al.

Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011; 124: 215–224.

Sahin

Duzgun

Tunc

Tutkak

. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Clin Rheumatol 2007; 26: 154–160.

Love

Santoro

. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682–698.

10.

Deak

Bocskai

Burcsar

Danyi

Fekete

Kovacs

. Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome. Lupus 2014; 23: 913–918.

11.

Tektonidou

Sotsiou

Nakopoulou

Vlachoyiannopoulos

Moutsopoulos

. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004; 50: 2569–2579.

12.

Afeltra

Garzia

Mitterhofer

et al.

Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108–110.

13.

Petri

Orbai

Alarcon

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

14.

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 2006; 4: 295–306.

15.

Pengo

Tripodi

Reber

et al.

Update of the guidelines for lupus anticoagulant detection. J Thromb Haemostasis 2009; 7: 1737–1740.

16.

Abreu

Danowski

Wahl

et al.

The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14: 401–414.

17.

Unlu

Zuily

Erkan

. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016; 3: 75–84.

18.

Hawro

Maurer

Sysa-Jedrjezowska

et al.

Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus. Br J Dermatol 2013; 168: 213–215.

19.

Garcia-Martin

Garcia-Garcia

Fraga

et al.

Prevalence of antiphospholipid antibodies in patients with subacute and chronic lupus erythematosus. Actas Dermo-Sifiliogr 2013; 104: 232–238.

20.

Ramos-Casals

Campoamor

Chamorro

et al.

Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13: 777–783.